Catalyst Dossier · compiled by Celia 🧫

Novartis AG (NVS)

Pharmaceutical Preparations · market cap $284.2B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-06-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Novartis AG (NVS) is a Swiss multinational pharmaceutical company, one of the world's largest by revenue, with a diversified pipeline spanning ophthalmology, oncology, cardiology, immunology, and rare diseases. The stock trades at approximately $148.93 with a market cap of ~$284B. Near-term attention centers on several high-importance catalysts including Phase 3 readouts for Remibrutinib (July 2026, imp 9/10), Fulvestrant (September 2026, imp 9/10), and Inclisiran sodium (October 2026, imp 9/10).

The catalyst path

2026-06-30 (est.)Phase 2 · 68Ga-FAP-2286imp 7/10
2026-07-16Earningsimp 5/10
2026-07-23 (est.)Phase 3 · Remibrutinibimp 9/10
2026-08-25 (est.)Phase 2 · JDQ443imp 7/10
2026-09-07 (est.)Phase 2 · EYU688imp 7/10
2026-09-15 (est.)Phase 3 · Fulvestrantimp 9/10
2026-09-21 (est.)Phase 2 · VHB937imp 7/10
2026-09-30 (est.)Phase 2 · cetuximabimp 7/10

Pipeline

Asset	Phase	Indication
Aflibercept 2 mg	Phase 3	Neovascular Age-related Macular Degeneration
Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)	Phase 2	Hormone Receptor Positive Breast Cancer
Certican®	Phase 3	Renal Interstitial Fibrosis
Verteporfin PDT	Phase 3	Pathological Myopia
Pemetrexed	Phase 3	Non-Small Cell Lung Cancer
Conventional Therapy	Phase 2	Non-infectious Intermediate Uveitis
[68Ga]Ga-PSMA-11	Phase 3	Prostatic Neoplasms
Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008	Phase 2	Influenza
Meningococcal (group B) multicomponent recombinant adsorbed vaccine.	Phase 2	Meningococcal Disease
AIN457 300 mg	Phase 3	Chronic Plaque Type Psoriasis
GSK2110183 (afuresertib)	Phase 2	Cancer
Octreotide (Immediate release)	Phase 2	Peritoneal Neoplasms
TMZ	Phase 2	Medulloblastoma
decitabine	Phase 2	Myelodysplastic Syndromes
QAV680	Phase 2	Seasonal Allergic Rhinitis
Midostaurin (PKC412)	Phase 2	Leukemia
VAK694; Alutard Avanz SQ	Phase 2	Seasonal Allergic Rhinitis
Vemurafenib	Phase 3	Melanoma
Chemotherapy	Phase 3	Acute Myeloid Leukemia (AML)
Indacaterol 150 μg capsules	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.